Podcasts about therapeutics

David Stamler, M.D., Chief Executive Officer AlterityTherapeuticsAlterity Therapeutics (NASDAQ: ATHE & ASX: ATH)www.alteritytx.com  David Stamler, M.D., Chief Executive OfficerDavid Stamler, M.D. is Chief Executive Officer and a Managing Director, and previously served as Alterity's Chief Medical Officer and Senior Vice President, Clinical Development. Dr Stamler has extensive drug development expertise spanning early-stage research through late-stage clinical trials, with three FDA drug approvals in neurology.Prior to joining Alterity, Dr. Stamler served as the Vice President, Clinical Development and Therapeutic Head for Movement Disorders at Teva Pharmaceutical Industries after Teva acquired Auspex Pharmaceuticals where he was Chief Medical Officer.Prior to Auspex, he served as Senior Vice President and Chief Medical Officer at XenoPort, Inc., and Head of Drug Development at Prestwick Pharmaceuticals, Inc. Before Prestwick, Dr. Stamler worked at Fujisawa Pharmaceutical Co. and its subsidiaries in various leadership roles, including Vice President, Research and Development, Medical Sciences at Fujisawa Healthcare, Inc., and as Vice President, Clinical Research Center at Fujisawa Research Institute of America. Dr. Stamler began his career at Abbott Laboratories where he served in various positions including Director of Clinical Research, Pharmaceutical Products for the International Division.Dr. Stamler received an M.D. from the University of Chicago—The Pritzker School of Medicine and a B.A. in Biology from the University of Chicago.

We love to hear from our listeners. Send us a message.In Episode 3 of our in vivo-focused special series of Cell & Gene: The Podcast, Ascidian Therapeutics' Founder, President, and CEO Mike Ehlers, M.D., Ph.D., explains how the company is advancing a new class of genetic medicines built on RNA exon editing to durably correct disease at the transcript level without permanently altering DNA. He also shares why in vivo therapies still need to prove precision, durability, and predictability before they become mainstream, and why the field must move beyond proof of concept to reproducible clinical performance across patients and diseases. He discusses the importance of patient selection, tissue specificity, and matching editing efficiency to biological thresholds, and much more. Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

The use of biotherapies has surged in recent years, creating new challenges and opportunities for pharmacy. In this episode, three experienced pharmacists in the world of biotherapeutic drugs will review key considerations for working with these agents. Their discussion will cover biosafety review processes and how to develop the structure to support ongoing management of biotherapeutics. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

A non-invasive Alzheimer's therapy is moving closer to patients, and it could reshape how brain health is treated. In this episode, Christian Howell, CEO of Cognito Therapeutics, joins Saul live at DeviceTalks Boston to discuss how the company is advancing a novel Alzheimer's therapy that uses sensory stimulation through light, sound, and touch. He shares insights from Cognito's HOPE study, the largest non-pharmacologic clinical trial in neurodegenerative disease, involving 673 participants across 70 sites. Christian explains why a strong evidence strategy is essential not only for regulatory approval but also for reimbursement, clinical adoption, and patient access. He also reflects on leadership lessons centered on service, humility, humor, and the importance of aligning stakeholders across the healthcare ecosystem to improve Alzheimer's care. Tune in to hear how Christian Howell and Cognito Therapeutics are working to bring new hope, stronger evidence, and a more accessible path forward for Alzheimer's patients and families! Resources: Connect with and follow Christian Howell on LinkedIn. Follow Cognito Therapeutics on LinkedIn and explore their website.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, shot live at the American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the latest major trial results like CONNECT, TRIUMPH, and TRANSCEND.To begin the episode, Isaacs and Bellini, discuss major highlights from ADA Scientific Sessions, focusing first on the landmark CONNECT trial evaluating continuous glucose monitoring (CGM) in people with type 2 diabetes who are not treated with insulin. They reflect on the evolution of CGM technology, from its early use primarily in type 1 diabetes to its expanding role in type 2 diabetes management, and explain why this trial represents an important step forward for patients who have historically had limited access to CGM.The hosts review the randomized controlled trial findings, emphasizing the significant improvements in glycemic outcomes, including a 1.6% reduction in A1c from baseline and an approximately 0.9% greater reduction compared with standard care. They also highlight the increase in time in range, with participants using CGM achieving roughly five additional hours per day in target glucose range. The magnitude of these findings is discussed as a practice-changing development, with the potential to influence future clinical guidelines and strengthen recommendations for CGM use among individuals with type 2 diabetes who are not using insulin.The discussion also explores the broader implications of the CONNECT trial for healthcare access and insurance coverage. The hosts note that randomized controlled trial evidence has historically played a key role in shaping standards of care and payer decisions, and they suggest that these results may help support wider adoption of CGM by demonstrating meaningful improvements in glucose control and patient outcomes.The conversation then shifts to emerging pharmacologic advances, with a focus on retatrutide, a novel triple agonist targeting GLP-1, GIP, and glucagon pathways. The hosts discuss new data showing substantial metabolic benefits in people with type 2 diabetes, including up to 17% weight reduction and nearly 2% A1c lowering. They highlight how these findings represent a major advancement in diabetes and obesity treatment, particularly as clinicians continue to see increasingly powerful effects from next-generation incretin-based therapies.Isaacs and Bellini explore how these therapies may reshape treatment strategies by allowing clinicians to tailor medication choices based on individual patient needs and goals. They discuss the importance of considering both glucose lowering and weight reduction effects, recognizing that some patients may benefit from significant weight loss while others may require a more balanced approach focused primarily on glycemic improvement.The hosts also address important unanswered questions surrounding the use of highly effective weight-loss medications, including appropriate treatment targets, the limitations of BMI as a measure, and the importance of preserving muscle mass and overall function. They emphasize the need to consider body composition, physical activity, resistance training, and patient characteristics—particularly in older adults or those at risk for frailty—when developing long-term treatment plans.The episode concludes with a reflection on the rapidly evolving landscape of diabetes care. The hosts highlight how advances in CGM technology and novel metabolic therapies are creating new opportunities to improve outcomes, personalize treatment approaches, and redefine the future management of people living with diabetes.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Kazmira Therapeutics is revolutionizing the CBD landscape by transitioning cannabinoids from over-the-counter health supplements to precision, pharmacist-compounded "real medicine". Led by co-founders Dr. Priyanka Sharma and Pulak Sharma, the company leverages proprietary precision-chemistry—rooted in her background as a chemical engineer—to ensure zero-THC, high-purity formulations. This clinical approach is increasingly relevant against the backdrop of significant regulatory changes, including the Schedule III reclassification of medical cannabis and recent federal legislation that further defines industrial hemp and hemp-derived cannabinoid products. These regulatory developments, which establish clearer standards such as a 0.4mg total THC limit, are dismantling the market's reliance on the confusing 0.3% dry-weight loophole and creating a "two-lane system" that prioritizes clinically supported, regulated products over speculative supplements.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Atossa Therapeutics CEO Steven Quayjoined Steve Darling from Proactive to discuss the continued advancement of the company's lead investigational therapy, (Z)-Endoxifen, and its potential applications across multiple breast cancer indications as well as certain rare diseases. The discussion highlighted the scientific foundation of the program, recent clinical data presentations, and key milestones expected in the months ahead. Quay explained that Atossa Therapeutics was founded with a clear mission focused on improving the prevention and treatment of breast cancer. Central to that strategy is the development of (Z)-Endoxifen, a therapy derived from decades of clinical experience and scientific understanding surrounding tamoxifen, one of the most widely prescribed treatments for hormone receptor-positive breast cancer. While tamoxifen has been a standard therapy for many years, its effectiveness depends on a patient's ability to metabolize the drug into its active form, Endoxifen. Quay noted that this process can vary significantly between individuals due to genetic differences and metabolic factors. Atossa's approach is to administer Endoxifen directly, potentially bypassing those limitations and providing more consistent therapeutic exposure across patients. According to Quay, clinical studies conducted to date have demonstrated encouraging signs of efficacy while maintaining what he described as a notably clean safety profile. The company believes the direct administration approach could offer meaningful advantages in both treatment and prevention settings. The CEO reviewed Atossa's clinical progress, noting that the company has successfully completed multiple Phase 2 clinical trials evaluating Endoxifen in various breast cancer settings. These studies have generated data supporting the continued advancement of the program and helping to define potential pathways toward later-stage development. The findings presented at ASCO generated considerable interest, particularly data suggesting that Endoxifen may remain active in breast cancers that have developed mutations commonly associated with resistance to endocrine therapies. Resistance to hormonal treatments remains a significant challenge in breast cancer management, and the possibility of maintaining therapeutic activity in resistant tumors could represent an important clinical opportunity. Quay noted that feedback from oncologists, researchers, and industry participants at ASCO was highly encouraging, particularly regarding the potential implications of the resistance-related findings. Management believes these observations could help differentiate Endoxifen from existing treatment options and support future development strategies. Looking ahead, Atossa plans to consolidate results from multiple ongoing and completed clinical programs to build a comprehensive dataset supporting future regulatory discussions. The company intends to engage with regulatory authorities and potential pharmaceutical partners as it evaluates the most effective path toward Phase 3 clinical development and eventual commercialization. #proactiveinvestors #nasdaq #atos #BreastCancer #Endoxifen #Biotech #Oncology #ClinicalTrials #CancerResearch #ASCO #DrugDevelopment #HealthcareInnovation

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this special episode, shot live at the American Diabetes Association (ADA) Scientific Sessions 2026 in Ner Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Amit Gupta, MBBS, DNB, diabetologist, executive director of the Global Metabolic Health Alliance, and chair of the International Diabetes Federation (IDF) Education Committee, to discuss the state of diabetes care and treatment in India compared to the US.To begin the episode, Gupta introduces the mission of the IDF, highlighting its role as a worldwide federation of scientific societies and patient organizations focused on improving diabetes education, policy, advocacy, and access to care. The conversation explores how diabetes management differs across regions, emphasizing that while the underlying disease mechanisms and available therapies may be similar, access to medications, technologies, healthcare infrastructure, and education varies significantly between countries.Gupta discusses the impact of semaglutide becoming available as a generic therapy in India following patent expiration, describing how reduced costs have improved access to a medication previously limited by affordability barriers. The group considers how increased availability of GLP-1 receptor agonists may transform diabetes and obesity management, while also emphasizing that pharmacologic therapies alone cannot address the global metabolic health crisis. Gupta notes the importance of maintaining focus on long-term lifestyle changes, including nutrition, physical activity, and sustainable weight management, as essential components of comprehensive care.The discussion then shifts to diabetes education and the need for more individualized, patient-centered approaches. Gupta highlights that education must be adapted to regional and cultural contexts, explaining that the challenges faced by a person with diabetes in the United States, Africa, India, or other parts of the world may differ substantially, even though diabetes distress and the burden of daily decision-making are shared experiences. He emphasizes that access to technology, such as continuous glucose monitoring, does not eliminate the need for education and support.Isaacs, Bellini, and Gupta also address the growing challenge of misinformation online and the role of healthcare professionals in helping patients navigate unreliable sources of health information. Gupta explains that clinicians must approach misinformation constructively by providing evidence-based guidance rather than simply dismissing patients' beliefs, reinforcing the importance of translating scientific evidence into practical recommendations that patients can incorporate into their daily lives.The group further examines disparities in the availability of diabetes educators worldwide. Gupta notes that while some regions have established professional pathways for diabetes care and education specialists, many areas lack standardized training, recognition, or policy support to sustain these roles. He stresses that building effective diabetes education systems requires collaboration with policymakers to demonstrate the long-term benefits of structured education programs.The episode concludes with Gupta discussing his work developing a global consensus framework on lifestyle as the foundation of metabolic health. The conversation reinforces that advances in medications and technology must be paired with equitable access, effective education, and sustainable lifestyle interventions to reduce the global burden of diabetes and improve outcomes for people living with metabolic conditions.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Gupta reports disclosures with Lilly, Abbott Diabetes, and the International Diabetes Federation.

Alissa Coram and Ed Carson walk through Tuesday's market action and discuss key stocks to watch in Stock Market Today. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of The Midweek Takeaway, Phil Carroll and Kevin Hornsby are joined by Sotirios Stergiopoulos, Chairman of Coiled Therapeutics, to discuss the company's recent progress and strategic developments. The conversation covers advances in its oncology programme, the strengthening of its scientific team, upcoming milestones, and the broader opportunities ahead as the company continues to develop its innovative therapeutic platform.Disclaimer & Declaration of InterestThis podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.

Coiled Therapeutics (AIM:COIL, OTCQB:COTXF) executive chairman Dr Sotirios Stergiopoulos joined Proactive's Stephen Gunnion to discuss the appointment of Professor Ozgur Sahin as a Scientific Advisor to the company and the progress of lead cancer therapy AO-252. Stergiopoulos explained why Sahin, a leading expert in TACC3 biology, is a key addition as the company advances the programme. He also highlighted encouraging early clinical data, including signs of tumour regression with no safety concerns reported to date, and outlined plans to begin dosing patients with a new AO-252 formulation in July. For more interviews and market insights, visit the Proactive YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications so you never miss future content. #CoiledTherapeutics #AO252 #PrecisionOncology #CancerResearch #Biotech #Oncology #ClinicalTrials #TACC3 #DrugDevelopment #HealthcareInnovation #CancerTreatment #MedicalResearch #Biotechnology #LifeSciences #ProactiveInvestors

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this special episode recorded live at the American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, welcome Trang Ly, PhD, MBBS, senior vice president and Chief Medical Officer at Insulet, to discuss the continued evolution of automated insulin delivery (AID) technology and emerging developments across the Omnipod platform. To begin the episode, Ly first reviews updates to Omnipod 5, focusing on enhancements aimed at increasing time in automated mode and improving glucose management. She explains that user feedback identified opportunities to support lower glucose targets and reduce interruptions related to system alerts. Data from real-world evidence and computer simulations suggest that lowering the glucose target from 110 to 100 mg/dL may lead to meaningful improvements in time in range and time in tight range without increasing hypoglycemia risk.The group discusses early clinical experience with these enhancements, including findings from users who transitioned to the updated system. Ly highlights that even a highly engaged population already using lower targets experienced additional improvements, including a 2% increase in time in range and a 5% increase in time in tight range over a short period of use. The conversation emphasizes the importance of making these improvements broadly available rather than waiting for routine follow-up visits, particularly given the potential benefits without additional safety concerns.The discussion then turns to Omnipod 6, with Ly sharing newly presented clinical trial data evaluating the next-generation system. She describes the study design, which enrolled users already achieving strong glycemic control on Omnipod 5 and assessed whether further intensification through algorithm improvements could safely provide additional benefits. The results demonstrated a 4% improvement in time in range and up to a 7% increase in time in tight range, with particularly notable improvements among individuals with type 1 diabetes aged 14 years and older.Ly explains that Omnipod 6 builds on previous technology through changes to the core algorithm, allowing the system to deliver more insulin when users do not bolus consistently. The panel explores how this approach may reduce the burden of diabetes management by allowing the algorithm to take on more responsibility while maintaining glycemic control. They discuss the potential psychological benefits of reducing the daily demands placed on people with diabetes, especially as sensor accuracy and automation continue to improve.The conversation also highlights future opportunities for AID in type 2 diabetes. Ly shares early feasibility data from a fully closed-loop system designed specifically for individuals with type 2 diabetes, emphasizing its simplified approach without requiring traditional pump programming or meal bolusing. In this study, participants experienced improvements in time in range, demonstrating the potential for automated insulin delivery to reach broader populations.Isaacs and Bellini discuss the need to reconsider barriers to insulin pump adoption in type 2 diabetes and recognize AID as an accessible option for patients who may benefit. Ly emphasizes that technology should support people across different levels of engagement, offering both highly customizable systems for those seeking intensive management and simpler automated approaches for those looking to reduce daily treatment demands.The episode concludes with a discussion of the future of diabetes technology, including improved connectivity, expanded device flexibility, and continued integration with complementary therapies such as GLP-1 receptor agonists. Ly underscores that innovation should not only improve clinical outcomes but also reduce the burden of care, allowing people with diabetes to spend less time managing their condition and more time living their lives.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Ly reports a disclosure with Insulet.References1: Insulet. Insulet Reveals New Data Supporting Breakthrough Omnipod 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care. June 6, 2026. Accessed June 7, 2026. https://investors.insulet.com/news/news-details/2026/Insulet-Reveals-New-Data-Supporting-Breakthrough-Omnipod-6-and-Fully-Closed-Loop-AID-Systems-Designed-to-Improve-Outcomes-Reduce-Effort-and-Unlock-Barriers-to-Care/default.aspx

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this special episode recorded live at the American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, welcome Ketan Dhatariya, MD, PhD, MS, consultant physician at Norfolk and Norwich University Hospitals, to discuss the evolving landscape of diabetes care, technology access, and clinical implementation. To begin the episode, Dhatariya shares his perspective on the challenges facing diabetologists, including workforce pressures, specialist training, and the difficulty of translating rapidly expanding diabetes guidelines and innovations into everyday clinical practice. The conversation then shifts to the differences between healthcare systems and how those structures influence access to diabetes therapies. Dhatariya discusses the UK's publicly funded healthcare model and the ongoing challenge of balancing the cost of emerging medications and technologies with their long-term benefits. He highlights the importance of demonstrating that investments in diabetes care today can reduce complications and healthcare costs in the future.Dhatariya then reviews the progress of continuous glucose monitoring (CGM) and automated insulin delivery (AID) adoption in the UK. He explains that CGM use among people with type 1 diabetes has become widespread, particularly among children, and that access to closed-loop systems continues to expand through structured implementation plans. He emphasizes the meaningful improvements these technologies have provided, including better glycemic outcomes among children and pregnant individuals, who may experience significant benefits from improved glucose management.The discussion explores how diabetes technology can support people with different lifestyles and challenges, while challenging assumptions about which patients may benefit most from advanced therapies. Dhatariya highlights that CGM and AID can provide valuable support for individuals who may struggle with traditional insulin management, while also emphasizing the need for appropriate education and follow-up to ensure safe and effective use.The group also discusses CGM use in type 2 diabetes and the growing evidence supporting broader access. Dhatariya explains that adoption has been slower because of the larger population affected by type 2 diabetes but notes emerging data suggesting CGM may help reduce complications, hospitalizations, and long-term healthcare costs. He describes the impact of seeing real-time glucose data, explaining how personal experience with CGM can help people better understand the relationship between food, behavior, and glucose patterns.The conversation then turns to access to GLP-1 receptor agonists in the UK and how healthcare systems determine eligibility for newer therapies. Dhatariya discusses the role of national guidance and health economic evaluations in balancing access, affordability, and sustainability. He highlights how improving obesity-related disease management may have broader benefits, including helping reduce the burden of diabetes, cardiovascular disease, and other chronic conditions.The episode also explores inpatient diabetes care and the increasing presence of diabetes technology in hospital settings. Dhatariya discusses guidance developed by the Joint British Diabetes Societies for Inpatient Care to help clinicians safely manage patients admitted while using CGM, insulin pumps, and AID systems. He emphasizes that devices should not automatically be removed and that patients may be able to continue using technology when they are well enough and capable of managing their systems.Finally, Dhatariya discusses the importance of structured diabetes education, including the DAFNE (Dose Adjustment For Normal Eating) program, which teaches carbohydrate counting, insulin adjustment, and self-management skills. He emphasizes that as diabetes technology becomes more advanced, education remains essential for both patients and clinicians. The episode concludes with a discussion of the need for continued advocacy, specialist care, and equitable access to ensure people with diabetes can benefit from ongoing advances in diabetes technology.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Dhatariya reports disclosures with AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this special episode recorded on-site at the American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, welcome Dr. Eugene Wright Jr., MD, the principal of Wright Health Care Solutions and a consulting associate in the department of medicine at Duke University Medical Center, to discuss the development of the ADA scientific statement on diabetes technology implementation in primary care. To begin the episode, Wright reflects on his career as an internist caring for patients with diabetes across diverse settings, including underserved communities where patients often faced significant barriers to accessing care. He describes how his experiences challenged assumptions about which patients would benefit from diabetes technology, noting that many under-resourced patients demonstrated strong engagement and improved self-management when given access to tools such as continuous glucose monitoring (CGM).The discussion focuses on the origins of the ADA scientific statement, which emerged from efforts to identify and overcome barriers limiting the adoption of diabetes technology in primary care. Wright explains that while diabetes technology has demonstrated significant benefits in improving outcomes and patient behaviors, implementation has remained slow in the settings where most people with diabetes receive care. The statement brought together key stakeholders, including clinicians, pharmacists, diabetes care and education specialists, patient representatives, and other experts, to develop practical strategies addressing policy, insurance, workflow, and clinical challenges.Isaacs, Bellini, and Wright explore how CGM can be successfully integrated into primary care by shifting the focus from simply providing access to using data effectively. Wright emphasizes that CGM and ambulatory glucose profile (AGP) reports allow clinicians to transform complex glucose data into actionable insights, helping identify patterns that may not be captured through A1C measurements or traditional glucose monitoring. The group discusses how CGM enables clinicians to ask better questions, uncover barriers to treatment, and engage patients in collaborative conversations without judgment.The hosts highlight the importance of building sustainable workflows, including preparing AGP reports before visits, assigning responsibilities across the care team, and identifying technology champions within practices. Wright explains that successful implementation requires recognizing the unique needs and resources of each primary care setting rather than applying a single model. They discuss the role of telehealth, clinical pharmacists, medical assistants, and other team members in supporting CGM initiation, interpretation, and ongoing management. The conversation also addresses how partnerships with technology manufacturers can simplify onboarding, training, troubleshooting, and patient support.The discussion then expands to insulin pumps and automated insulin delivery systems, with the group noting how advances in technology have reduced complexity and made these therapies more accessible for people with type 2 diabetes. Wright describes how newer systems can help reduce the daily burden of diabetes management by automating adjustments and supporting patients in achieving their goals. The hosts emphasize that diabetes care should move beyond focusing only on glucose metrics and instead consider the lived experience of patients, including the constant decision-making and emotional burden associated with managing diabetes.The episode concludes with a broader call to action for expanding access to diabetes technology across all healthcare settings. Wright emphasizes that many patients do not have access to endocrinology care but still deserve the benefits of modern diabetes tools. The scientific statement represents the beginning of an ongoing effort to improve implementation, strengthen collaboration among stakeholders, and ensure that diabetes technology reaches all patients who can benefit from it.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Wright Jr. reports disclosures with Abbott Diabetes, Bayer AG, Boehringer Ingelheim, Lilly, and Sanofi.ReferencesSection 7: Diabetes technology. Diabetes Obesity and Cardiometabolic CARE. Published online March 23, 2026. doi:10.2337/doc26-a007

We love to hear from our listeners. Send us a message.In episode 130 of Cell & Gene: The Podcast, Dr. Naji Gehchan, Chief Medical and Development Officer at Kyverna Therapeutics, joins Host Erin Harris to outline the company's mission to apply CAR T-cell therapy beyond oncology to treat severe autoimmune diseases, highlighting promising Phase 2 data from its investigational therapy, Miv-cel, in stiff person syndrome (SPS). Dr. Gehchan explains that Miv-cel works by deeply depleting pathogenic B cells and enabling a broad immune reset, differentiating it from conventional therapies that require ongoing management. As Kyverna advances a rolling BLA submission, Dr. Gehchan positions this milestone as potentially historic, both for SPS patients and for the broader cell therapy field, signaling an inflection point where CAR T could transform autoimmune disease care in the same way it has oncology.Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

Jake Becraft is the CEO and co-founder of Strand Therapeutics, a company building one of the most advanced programmable genetic medicine platforms in biotechnology. Under his leadership, Strand is redefining what RNA medicines can do by enabling cell-selective targeting and therapeutic payload delivery inside the body, unlocking a new class of precision genetic therapies.This episode is brought to you by:Helix Sleep premium mattresses: HelixSleep.com/Tim (20% off any purchase) Incogni, which automatically removes your personal data from the web, helping shield you from fraud, scams, and identity theft: Incogni.com/Tim (use code TIM at checkout and get 60% off an annual plan)*For show notes and past guests on The Tim Ferriss Show, please visit tim.blog/podcast.For deals from sponsors of The Tim Ferriss Show, please visit tim.blog/podcast-sponsorsSign up for Tim's email newsletter (5-Bullet Friday) at tim.blog/friday.For transcripts of episodes, go to tim.blog/transcripts.Discover Tim's books: tim.blog/books.Follow Tim:Twitter: twitter.com/tferriss Instagram: instagram.com/timferrissYouTube: youtube.com/timferrissFacebook: facebook.com/timferriss LinkedIn: linkedin.com/in/timferrissSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of the AI Agent & Copilot Podcast, Giuseppe Ianni, AI Practice Lead and industry thought leader, is joined by Nandita Puri, PhD Candidate at Georgia Tech and founder of Illumia.bio. Puri discusses how AI is transforming drug discovery by creating massive therapeutic libraries, connecting fragmented biomedical knowledge, and dramatically accelerating research timelines. Their conversation explores the convergence of AI, structural biology, and life sciences. Key Takeaways AI Expands the Search Space for New Therapeutics: Traditional drug discovery focuses on identifying a single drug for a single target, but Puri argues that diseases are complex biological systems requiring broader approaches. Her team is building an AI-generated library of more than 10 billion molecules across multiple therapeutic modalities. By treating drug discovery as a combinatorics problem, researchers can explore vastly larger therapeutic possibilities. Connecting Fragmented Scientific Knowledge Accelerates Discovery: One of the biggest bottlenecks in pharmaceutical research is the fragmented nature of scientific information. Researchers often spend years reviewing hundreds of papers before forming a hypothesis. Puri describes how her team is integrating 60 to 70 public databases into a connected knowledge platform that links diseases, genes, proteins, pathways, and drug candidates. As she notes, "When we type a disease, we know exactly the gene, we exactly know the protein." This consolidation dramatically reduces research time and enables scientists to make more informed decisions earlier in the discovery process. AI Creates New Opportunities for Rare Disease Research: Rare diseases have historically been underserved because of the high costs and long timelines associated with traditional drug development. Puri says that bringing a drug to market can require "$1 billion and about 10 years." By shortening research cycles from years to months, AI lowers the barriers to investigating diseases that pharmaceutical companies may have previously avoided. This acceleration enables smaller teams to pursue treatments for conditions affecting fewer patients while increasing the likelihood that promising therapies can move forward to validation and clinical testing. Visit Cloud Wars for more.

Racheli Ofir is the CEO and CTO of Betalin Therapeutics, an Israeli company developing a biological micropancreas that could one day offer a one-time cure for insulin-dependent diabetes — replacing the missing pancreatic function with living cells that sense glucose and respond in real time. Avraham sat down with Racheli to discuss how the technology works, what their animal trials showed, why IP is critical, the challenges of funding a biotech startup in wartime Israel, her advice for founders just getting started and much more. Do you have a great innovation? We'd love to hear from you. Contact us by going to https://jmbdavis.com/startup/contact. Learn more at https://jmbdavis.com and https://jmbdavis.com/startup. Also available at https://soundcloud.com/jmbdavis/ betalin. Listen to all of the episodes at https://jmbdavis.com/podcast.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent FDA approval of MannKind's inhaled insulin Afrezza for pediatric patients aged 6 years and older with both type 1 and type 2 diabetes, describing the decision as a major milestone in diabetes therapeutics and the first expansion of the therapy beyond adults. The episode centers on the clinical implications of the approval, the pharmacologic advantages of inhaled insulin, and the practical considerations surrounding implementation in pediatric care settings.The hosts review findings from the INHALE-1 trial, which enrolled 230 pediatric participants aged 4 to 17 years and compared inhaled insulin used alongside basal insulin with standard multiple daily injection (MDI) therapy over 56 weeks. Bellini emphasizes that the study achieved its primary objective of demonstrating glycemic outcomes comparable to traditional insulin regimens, noting that insulin studies are generally designed to establish equivalence rather than superiority. Beyond similar glycemic control, the hosts highlight several clinically meaningful secondary observations, including stable BMI among participants receiving inhaled insulin compared with weight gain in the MDI cohort, increased treatment satisfaction reported by both adolescents and parents of younger children, comparable hypoglycemia rates, and the absence of new safety concerns. Bellini also notes that no decline in lung function was observed among participants using inhaled insulin, despite historical concerns surrounding pulmonary safety with inhaled therapies.A major focus of the discussion is the physiologic pharmacokinetic profile of Afrezza, which Isaacs characterizes as the most physiologic insulin currently available. She explains that inhaled insulin demonstrates measurable activity within approximately 12 minutes, peaks within 35 to 45 minutes, and clears the bloodstream in roughly 90 minutes. The hosts contrast this with subcutaneous rapid-acting insulin analogs, including ultra-rapid formulations, which retain a prolonged “tail” of insulin activity that can increase hypoglycemia risk. Isaacs and Bellini suggest that the shorter duration of inhaled insulin may reduce the cycle of overtreating hypoglycemia and subsequent rebound hyperglycemia, thereby potentially contributing to the absence of weight gain observed in the trial. Bellini further emphasizes that the rapid onset and offset of inhaled insulin restore some of the flexibility and spontaneity often lost in intensive insulin therapy, particularly around meal dosing and correction strategies.The conversation also situates inhaled insulin within the broader framework of individualized diabetes management and the ADA Standards of Care. Isaacs stresses that the approval should not be viewed as competing with automated insulin delivery (AID) systems, but rather as expanding patient choice. The hosts discuss how inhaled insulin may be especially valuable for individuals who do not wish to wear insulin pumps, desire periodic breaks from technology, or want to reduce the burden of injections. Isaacs additionally highlights the growing prevalence of pediatric type 2 diabetes and notes that, despite advances in incretin-based therapies, many youth still require insulin therapy. In that context, the possibility of pairing inhaled mealtime insulin with emerging once-weekly basal insulin formulations and GLP-1 receptor agonists is presented as a potentially transformative strategy for minimizing injection burden.Bellini and Isaacs also address practical implementation challenges within school settings. Because inhaled insulin acts rapidly, Bellini notes that administration timing may need to shift from the nurse's office to the cafeteria environment to avoid hypoglycemia if meals are delayed. At the same time, both hosts recognize that the flexibility of postprandial dosing could offer advantages for children with inconsistent eating patterns or concerns about privacy surrounding insulin administration. They further discuss the utility of inhaled insulin for rapid glucose corrections, noting that additional doses can be administered far sooner than with traditional injected rapid-acting insulin.The episode concludes with discussion of anticipated affordability initiatives from MannKind Corporation, including bridge programs designed to improve early access and reduce financial barriers to therapy. Isaacs and Bellini commend the company's efforts to secure pediatric approval and express optimism that broader availability of inhaled insulin will expand individualized treatment options, improve patient satisfaction, and enhance quality of life for children and adolescents living with diabetes.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.References1: HOLDER

Send us Fan MailWhat if medicines could actually “decide” when and where to activate inside the body? MIT-trained synthetic biologist Dr. Jacob Becraft, Ph.D. is building programmable therapies that behave less like traditional drugs…and more like biological software.Dr. Becraft is Co-Founder and CEO of Strand Therapeutics ( https://www.strandtx.com/ ), a company pioneering what may become one of the next great frontiers in medicine: programmable mRNA therapeutics.Long before mRNA became a household term through COVID vaccines, Dr. Becraft and his colleagues at MIT were developing what has been described as the world's first synthetic biology programming language for mRNA - technology designed not simply to deliver genetic instructions, but to create logic-driven therapies capable of making decisions inside living cells.Now Strand is translating that vision into cancer therapeutics, with early clinical data from its lead candidate STX-001 showing responses in patients with advanced solid tumors who had exhausted conventional options - including evidence of systemic immune activity and even complete responses.Beyond the science, Jake is also a leading voice in synthetic biology, biotech entrepreneurship, and the future relationship between software, biology, and medicine.#StrandTherapeutics #JacobBecraft #SyntheticBiology #mRNA #ProgrammableMedicine #CancerImmunotherapy #Immunotherapy #Biotech #PrecisionMedicine #GeneTherapy #SyntheticBiologyEngineering #FutureOfMedicine #Oncology #CAR_T #mRNATherapeutics #Bioengineering #IL12 #RNA #MIT #CellTherapy #Longevity #Biotechnology #MedicalInnovation #NextGenMedicine #CancerResearch #AIinBiology #HealthcareInnovation #GeneticMedicine #ScientificBreakthrough #ProgressPotentialPossibilitiesSupport the show

Pancreatic cancer is a devastating diagnosis, and the statistics are alarming. According to the latest research, it's the third leading cause of cancer-related deaths in the US, with over 50,000 people losing their lives each year. The disease is particularly aggressive, with a survival rate of just six to seven months after diagnosis. In this episode, our guest, Dr. Greg Verdine, shares his insights on a promising new treatment that could reshape the way we approach pancreatic cancer. Dr. Verdine, a professor of chemistry at Harvard and CEO of LifeMine Therapeutics, discusses the challenges of treating pancreatic cancer, including its tendency to be asymptomatic until late stages and its resistance to chemotherapy. He explains how a new daily pill, currently in early trial stages, targets the cancer's genetic mutations and has shown promising results in extending patients' lifespans. The conversation delves into the complexities of pancreatic cancer, including its unique characteristics that make it difficult to treat. Dr. Verdine highlights the importance of this new treatment, which has the potential to double patients' lifespans and pave the way for further research. If you're interested in learning more about this breakthrough treatment and the future of pancreatic cancer research, tune in to this episode to hear Dr. Verdine's expert insights and the potential for a brighter outlook on this devastating disease.See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a myriad of events shaping the industry, ranging from regulatory hurdles to strategic acquisitions and scientific breakthroughs. A significant milestone has been achieved by Outlook Therapeutics with its product Lytenava (bevacizumab), which recently won an appeal with the FDA for wet age-related macular degeneration treatment. This antibody therapy, aimed at VEGF inhibitors, marks a notable advancement in ophthalmology, potentially transforming management strategies for this debilitating condition. Monoclonal antibodies like Lytenava continue to underscore their importance in treating chronic diseases, offering hope for patients and setting benchmarks for similar therapeutic innovations. On a less favorable note, AstraZeneca encountered a setback when their breast cancer treatment camizestrant faced rejection from an FDA advisory committee. Despite robust phase 3 data for hormone receptor-positive breast cancer, the advisory committee's decision delays the drug's review process. This serves as a stark reminder of the stringent requirements oncology treatments must meet and highlights the critical need for comprehensive clinical data to ensure patient safety and drug efficacy in this competitive field. Amidst these developments, Astellas is proactively addressing upcoming patent expirations, particularly for Xtandi in 2026. The company has announced a five-year growth strategy focused on pipeline acquisitions, illustrating broader industry trends where diversifying portfolios through acquisitions and partnerships is crucial for maintaining competitiveness and delivering innovative therapies. Business development activities continue to be a highlight within the sector. Apogee Therapeutics and Blackstone Life Sciences have entered into a $1.3 billion royalty financing agreement to advance an eczema drug, underscoring ongoing investments in autoimmune treatments. Similarly, AGC Biologics' partnership with Teikoku Seiyaku on microbial CDMO services aims at advancing musculoskeletal therapies, showcasing how collaborations can leverage specialized manufacturing capabilities for therapeutic progress. Clinical trials also made headlines as Junshi Biosciences reported that its drug toripalimab met primary endpoints in phase 3 trials for non-small cell lung cancer perioperative treatment. This achievement underscores the growing influence of immunotherapies in oncology, promising improved surgical outcomes and enhancing their role within cancer treatment paradigms. Funding continues to play a pivotal role in sustaining innovation within the industry. Editas Medicine recently raised $125 million to propel its CRISPR-based gene therapy pipeline forward. Such financial backing is instrumental in transitioning promising therapies from preclinical stages to market readiness, ensuring that groundbreaking science translates into patient-accessible treatments. Regulatory landscapes remain dynamic, with ongoing discussions about updating COVID-19 vaccine formulations to target emerging subvariants. The FDA's commitment to adapting vaccine guidelines reflects a proactive stance in infectious disease management, crucial for maintaining vaccine efficacy against evolving pathogens. In acquisition news, Olympus' purchase of Bioprotect for $270 million adds biodegradable balloon spacer technology to its prostate cancer radiation therapy offerings. This acquisition highlights how medical device innovations can complement pharmaceutical approaches, enhancing treatment efficacy and patient quality of life. These developments collectively paint a vibrant picture of the biotech and pharmaceutical industries—a landscape where scientific advancements, regulatory challenges, strategic planning, and financial investments converge. The implications are far-reaching, potentially redefining treatment paradigms across various therapeutic areas as these sectors continue their pursuit of innovation and improved patient care outcomes. Navigating this landscape also involves addressing broader challenges such as policy shifts and pricing pressures within key markets like the United States. Companies must remain adaptable, balancing growth strategies with compliance demands amidst changing regulatory environments—a theme echoed by recent surveys indicating heightened pressure on healthcare firms to maintain profitability. Moreover, geopolitical considerations are influencing cross-border investments in biotechnology as policymakers debate strategies best suited for managing foreign influence—reflecting broader concerns about national security and economic competitiveness within this critical sector. As we continue monitoring these dynamic shifts within pharmaceuticals and biotechnology, it's evident that scientific innovation remains tightly interwoven with regulatory scrutiny and financial dynamics. The ongoing dance between these elements will undoubtedly shape future trajectories in healthcare advancements globally, promising new horizons in patient care while addressing pressing health challenges worldwide. That's all for today's episode of Pharma Daily—where we keep you informed on the latest developments driving progress within pharmaceuticals and biotechnology. Thank you for tuning in; until next time!Support the show

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss several major developments in diabetes technology and obesity therapeutics, beginning with Abbott's announcement that its dual glucose-ketone monitoring systems, Libre Duo and Libre Duo 10 Day, have received CE mark approval in Europe. The hosts describe the devices as the first continuous glucose-ketone monitors capable of simultaneously measuring glucose and ketone levels through a single wearable sensor, with real-time ketone monitoring intended to identify rising risk for diabetic ketoacidosis (DKA). Bellini explains the rationale for separate 15-day adult and 10-day pediatric sensors, noting higher sensor failure rates and greater activity levels in children. Both hosts emphasize the potential clinical significance of continuous ketone monitoring, particularly for individuals with type 1 diabetes (T1D) using insulin pumps, where interruptions in insulin delivery can rapidly precipitate DKA.The discussion further explores how continuous ketone monitoring may expand the safe use of SGLT2 inhibitors in people with T1D and other high-risk populations. Bellini highlights concerns surrounding euglycemic DKA associated with SGLT2 inhibitor therapy and suggests that continuous ketone data could help clinicians identify susceptible individuals earlier, potentially enabling safer and more individualized dosing strategies. Isaacs underscores the limitations of current ketone testing methods, particularly urine ketone testing, which she characterizes as outdated and insufficient for modern diabetes management. The hosts also review additional patient populations that may benefit from continuous ketone monitoring, including individuals with recurrent DKA, pediatric patients with highly variable glycemic patterns, and hospitalized patients at elevated risk for ketosis due to prolonged fasting or treatment interruptions.Isaacs and Bellini also consider practical questions surrounding implementation, including reimbursement, cost, workflow integration, and compatibility with automated insulin delivery systems. They discuss whether continuous ketone monitoring could eventually become standard of care in T1D and debate the broader implications of widespread ketone data availability, including potential consumer interest outside traditional diabetes populations. Both hosts stress the importance of prioritizing access for patients at highest risk for DKA while acknowledging that broader adoption could reshape diabetes monitoring paradigms similarly to the evolution of continuous glucose monitoring.The episode then turns to recent reports involving Dexcom sensors that were reportedly stolen after being removed from the manufacturing process for quality concerns. Bellini explains that some of the affected sensors may not have completed sterility and quality assurance procedures before entering secondary markets. The hosts caution clinicians to review affected lot numbers and encourage ongoing vigilance until additional information becomes available. They also discuss the challenges of communicating recalls and safety alerts directly to patients, particularly for users relying on standalone receivers that may not connect to cloud-based notification systems.Finally, Isaacs and Bellini review newly released topline results from the phase 3 TRIUMPH-1 trial evaluating retatrutide, Lilly's investigational triple agonist targeting GLP-1, GIP, and glucagon receptors. Bellini summarizes findings demonstrating substantial weight reduction among adults with obesity or overweight without diabetes, including mean weight loss exceeding 28% at 80 weeks and continued weight reduction through 104 weeks without evidence of plateau. The hosts note that nearly half of participants achieved at least 30% weight loss, approaching outcomes historically associated with bariatric surgery. They also highlight low discontinuation rates and discuss the implications of future TRIUMPH studies evaluating retatrutide in patients with type 2 diabetes and cardiovascular disease. Isaacs concludes that the emerging data signal a transformative shift in obesity treatment, with pharmacologic therapies increasingly approaching surgical efficacy and potentially reshaping long-term obesity management strategies.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

What does it really take to progress from bench science to leading a Biotech platform as Chief Scientific Officer? In this episode of Careers in Discovery, Daniel Tardiff, CSO at Camp4 Therapeutics, shares a candid look at building and scaling science inside an early‑stage biotech. From his foundations in RNA biology to advancing antisense programmes for haploinsufficiency-driven neurodevelopmental disorders, Dan unpacks how translational judgement is developed over time, not taught. Key takeaway: Career progression isn't about having perfect answers. It's about making credible decisions under uncertainty and bringing others with you as the science scales.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Neil McFarlane, CEO at Zevra Therapeutics, talks about transitioning to a focused rare disease company through acquisitions, and building out a commercial organization. Neil explains the importance of working with rare disease patient advocacy groups, using AI to analyze electronic health records and claims data to identify and diagnose patients with Niemann-Pick disease type C, and adapting to regulatory inconsistencies around rare disease drug approval frameworks in the U.S. and Europe.     Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

A conversation with Dr. Babak Kateb Find the video of this conversation at https://youtu.be/GbnIhjO_Af0 Find more at https://www.worldbrainmapping.org/

We love to hear from our listeners. Send us a message.In episode 129 of Cell & Gene: The Podcast, Host Erin Harris reconnects with Zachary Roberts, M.D., Ph.D., EVP of Research & Development and Chief Medical Officer at Allogene Therapeutics, to explore how allogeneic CAR-T is evolving from a scalability promise into an earlier-line, potentially curative intervention. Their conversation centers on the ALPHA3 trial, where MRD-guided treatment is redefining when and how CAR-T can be deployed, alongside broader implications for diagnostics, patient access, and the shift toward off-the-shelf therapies in community settings.Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

Send us Fan MailIn the time it will take you watch this episode, over 2,000 people around the world will die from diseases driven by arterial plaque. But what if we could actually remove the toxic cholesterol already trapped inside arteries?Today we're diving into one of the biggest unsolved problems in medicine and aging: how do you actually remove arterial plaque instead of merely slowing its progression?Cardiovascular disease remains the world's leading killer, despite decades of statins, anti-inflammatory drugs, and newer RNA-based therapies. Most existing treatments help manage cholesterol and reduce risk, but very few directly target the toxic debris already embedded inside plaques.But what if we could literally extract some of the most dangerous oxidized cholesterol molecules from the body?My guest today is Dr. Matthew ‘Oki' O'Connor, Ph.D. - CEO and Co-Founder of Cyclarity Therapeutics ( https://cyclaritytx.com/ ), a biotech company developing engineered cyclodextrin molecules designed to bind and remove 7-ketocholesterol, or 7KC - a toxic oxidized cholesterol strongly implicated in atherosclerosis, inflammation, plaque instability, and even broader age-related diseases.Just recently, the company presented first-in-human clinical data at the American Heart Association Vascular Discovery Scientific Sessions showing dose-dependent urinary excretion of 7KC - potentially the first clinical evidence that this toxic molecule can be safely mobilized and removed from the human body.We'll discuss what 7KC actually is, why oxidized cholesterol may be a root driver of cardiovascular disease, how engineered cyclodextrins work like molecular “sponges,” what the new human data really shows - and what it would mean if medicine could move from slowing plaque progression to truly reversing it.#HeartDisease #Atherosclerosis #Longevity #CardiovascularDisease #PlaqueReversal #AgingResearch #Biotech #Cholesterol #OxidizedCholesterol #7Ketocholesterol #Cyclarity #Healthspan #PrecisionMedicine #AIinBiotech #DrugDiscovery #PreventiveMedicine #Cardiology #AntiAging #Lifespan #MedicalInnovation #SENS #FoamCells #Plaque #HeartAttack #StrokePreventionSupport the show

This interview is disseminated on behalf of Cardiol Therapeutics Inc.In this episode of Stocks to Watch, we sit down with David Elsley, President and CEO of Cardiol Therapeutics (NASDAQ: CRDL | TSX: CRDL), to discuss the company's late-stage clinical development program targeting inflammation-driven heart conditions, including recurrent pericarditis and acute myocarditis.Learn more: https://www.cardiolrx.comWatch the full YouTube interview here: https://youtu.be/NXkzgfWHQnAAnd follow us to stay updated: https://www.youtube.com/GlobalOneMedia 

In this episode of Careers in Discovery, Adrian Gabriel Torres, Chief Scientific Officer at Aptadel Therapeutics, talks about developing RNA aptamer–based cancer therapies and leading scientific strategy in a preclinical biotech start-up. Adrian also shares his journey from academic research into industry, reflecting on the differences between academia and biotech, learning new skill sets, managing teams, and making career decisions along the way.

Rakhi Melvani, M.D., board-certified cornea and cataract and refractive surgeon at Gordon Schanzlin New Vision Institute, joins the Eye on Innovation podcast with host Carey Powers, M.B.A. to discuss innovative corneal treatments and how they're changing the way patients receive treatment. Their conversation explores the FDA approval of Epioxa, an epithelium-on corneal collagen cross-linking therapy to treat progressive keratoconus, as well as refractive surgery and dry eye therapies.   In this episode, learn about:  Ray tracing-based customization technology and how it's different from Lasik Collagen mimetic peptides and how they work ST100 and the patients that would benefit from it  RESOURCES:  Carey Powers: https://ois.net/carey-powers/  

In this episode of The Sunday Roast, Phil Carroll and Kevin Hornsby discuss the latest political and geopolitical developments impacting global markets, including UK election results, tensions in the Middle East and the wider effect on commodities and investor sentiment.The show also features an interview with Dr Sotirios Stergiopoulos from Coiled Therapeutics plc , discussing the company's oncology platform, progress around  AO-252  and its potential across multiple cancer indications.Later in the episode, Charles Archer joins the show alongside David Minchin from Halo Minerals Plc to discuss permitting progress, project development, financing strategy and future catalysts across the company's portfolio.00:00 - 00:05:32 Weekly News Roundup00:05:32 #COIL Interview00:38:38 #HALO Interview01:02:32 #EPP 01:04:15 #DGQ01:05:50 #KEN 01:07:44 #AEG Disclaimer & Declaration of InterestThis podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.

Dr Simon Dean is an ophthalmologist based in New Zealand with a keen interest in optoelectronics. In 2007 he was awarded fellowship of the Royal Australian and New Zealand College of Ophthalmologists (FRANZCO). He completed fellowship training in the UK in oculoplastics and ocular oncology in Glasgow, followed by cataracts and anterior segment in Birmingham, UK, and the Bedford branch of Moorfields Eye Hospital. He also holds fellowship of the British Contact Lens Association (FBCLA) by examination. He completed his MSc in cataract and refractive surgery in 2009. Dr Dean was Head of Department at Manukau Superclinic for seven years, and consults privately through re:vision a boutique cataract and refractive clinic in Auckland. He was the Subject Leader for the RANZCO Optics exam team for 12 years and recently promoted within the College to Chair of the basic sciences and COPEM. Dr Dean is active in teaching and research and has designed and built a number of ophthalmic instruments, including a corneal collagen crosslinking device. He is inventor of the Photon Therapeutics device having built the first prototypes and coordinated the research to support this novel technology. When he is not accompanying his two boys to their many extracurricular activities, he can be found either on a mountain bike, climbing, or playing double bass in the St Matthews Chamber Orchestra. He is married to ocular surface research pioneer Professor Jennifer Craig.Check out Photon TherapeuticsCome check us out at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Ashburton Eyecare⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/ashburton.eyecare/Instagram https://www.instagram.com/ryanoconnornz/  Instagram https://www.instagram.com/stagryan/  Twitter https://twitter.com/stagryan  Tik Tok @ryanstagoconnor  Facebook https://www.facebook.com/WaiKeto/  Blog https://stagryan.com/

In this episode of The Sunday Roast, Phil Carroll, Kevin Hornsby and Charles Archer discuss the latest global developments impacting markets, including geopolitical tensions in the Middle East and their effect on energy and investor sentiment.The show features interviews with Rift Helium, Solvonis Therapeutics plc, and Karelian Diamond Resources. Discussions cover helium exploration and market dynamics, advances in biotech and drug development strategy, and updates on diamond exploration and recent drilling progress.The episode wraps up with the latest market movers, fundraises, and commentary across key sectors.00:00 - 00:06:02 Weekly News Roundup00:06:02 #RIFT Interview00:47:38 #SVNS Interview01:16:25 #KDR Interview01:42:43 #DELT 01:43:26 #QDE 01:45:49 #AEG 01:47:34 #ONDO 01:51:24 #DELTA Disclaimer & Declaration of InterestThis podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast. 

Send us Fan MailFor decades, Parkinson's patients have been offered only symptom management. No drug has ever slowed the disease itself. A small clinical stage biotech may be about to change that.Gene Mack, CEO, Gain Therapeutics joins host David E. Williams to discuss the science behind a potential first disease modifying therapy for Parkinson's, how AI is accelerating drug discovery, and what it takes to build a biotech in one of the toughest capital markets in years.

There are few neurodegenerative diseases as devastating as Huntington's. It's sometimes likened to having Parkinson's, ALS and Alzheimer's all at the same time, with symptoms that include progressive motor dysfunction, cognitive decline and behavioural change. It's also hereditary — if a person has the faulty gene that causes the disease, there's a 50 percent chance their children will have it, too. In the fall of 2025, however, scientists announced that, for the first time, they could reduce the progression of Huntington symptoms using a new gene therapy. While that clinical breakthrough came with several caveats, it also heralded a possible new paradigm for drug discovery. In this episode, we explore how this innovative therapy works and what it could mean for the treatment of other rare diseases.  Featured in this episode: Rachel Harding is an assistant professor in the department of pharmacology and toxicology at the University of Toronto and a principal investigator at the Structural Genomics Consortium. Her work on Huntington's disease has been recognized with major early-career awards, highlighting both scientific excellence and the potential patient impact of her research program. Further reading: Research is unravelling the mystery of what causes Huntington's disease, a devastating brain disease In a first, a gene therapy seems to slow Huntington disease “Best news” for Huntington's disease community comes with unanswered questions The Huntington's disease research pipeline World's first patient treated with personalized CRISPR gene editing therapy at Children's Hospital of Philadelphia Solve for X is brought to you by MaRS, North America's largest urban innovation hub and a registered charity. MaRS supports startups and accelerates the adoption of high-impact solutions to some of the world's biggest challenges. For more information, visit marsdd.com.

Data monitoring committee recommends proceeding with registration-enabling study for ATSN-201

This episode features Marwan G. Fakih, MD - Medical Oncologist, Professor, Department of Medical Oncology & Therapeutics Research, Deputy Director, City of Hope Comprehensive Cancer Center, Division Chief, GI Medical Oncology, Co-director, Gastrointestinal Cancer Program at City of Hope. Here he shares his thoughts around potentially screening younger patients, due higher rates of colon cancer. He also discusses the importance of educating patients to not overlook potential symptoms, clinical trials, and more.

This episode features Marwan G. Fakih, MD - Medical Oncologist, Professor, Department of Medical Oncology & Therapeutics Research, Deputy Director, City of Hope Comprehensive Cancer Center, Division Chief, GI Medical Oncology, Co-director, Gastrointestinal Cancer Program at City of Hope. Here he shares his thoughts around potentially screening younger patients, due higher rates of colon cancer. He also discusses the importance of educating patients to not overlook potential symptoms, clinical trials, and more.

Robert Schickel, Chief Executive Officer at NUAgo Therapeutics, is developing a cancer therapy using short RNAs to target and disrupt interconnected survival genes in cancer cells. The therapy has been shown to be non-toxic to healthy cells, which have high levels of microRNAs, whereas cancer cells downregulate microRNAs to become metastatic. This is a systems-biology therapeutic approach that targets the entire survival network of a cell, making it independent of specific mutations or pathways and potentially applicable to the vast majority of solid tumors. Robert explains, "NUAgo is a technology company. We are developing what we define as short RNAs, and these are going to be cancer therapies that really target the survival system of a cancer. This survival system keeps the cancer alive. And instead of going after single components, pathways, or mutations as targeted therapies do, we're using short RNAs to reduce the expression of multiple essential survival genes. And when you get enough of these genes disrupted, the cancer cells can no longer maintain the system that keeps them alive. And at that point, the cell will activate a death response that eliminates the cancer cell by activating several cell death pathways simultaneously. So this is really a unique area in science, and we're developing this. It's a new modality. You see a lot of promise of this in the solid tumor patients."   "The platform that we're building has the potential to go across solid tumor markets. The recent IP that we're filing is for the 11 largest tumor markets from breast and lung, kidney, liver, and all the way down to the smaller, more lethal cancers in pancreas, ovarian, and other small cancers as well. So right now we think we can apply this to about 85% or 90% of the market."   "What we're doing is we take a step back. We're in fundamental biology. So this mechanism really goes back almost a billion years. I mean, fungi have the same mechanism. And so when we go after what are called survival genes, and they are essential for the survival of a cell, they deal with all kinds of cellular functions." #NUAgoTherapeutics #CancerResearch #Oncology #Biotechnology #PrecisionMedicine #RNATherapeutics #SystemsBiology #MedicalInnovation #HealthcareBreakthrough #CancerTreatment #SurvivalGenes #BiopharmaDevelopment NUAgotherapeutics.com Download the transcript here

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we speak with Dr. Sarfaraz Niazi, Ph.D., about how biosimilar regulations have taken shape, from early FDA uncertainty to citizen petitions, lawsuits, and guideline changes. Dr. Niazi offers a behind the scene look at the way FDA policy gets made, and unmade, and his own role in key regulatory changes, and legislation such as the Biologics Price Competition and Innovations Act (BPCIA), and the Inflation Reduction Act (IRA). We also discuss Dr. Niazi's current company, RNA Therapeutics, and his quest to make new drug modalities accessible to patients around the world.     This episode of the Business of Biotech is brought to you by Cytiva. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

In this episode, we explore the rapidly evolving field of regenerative medicine, focusing on a cutting-edge approach known as RPA (Regenerative Protein Array). Joined by leading medical experts, we break down how RPA differs from traditional therapies like PRP and stem cells, and how it leverages a complex network of proteins to support healing, recovery, and performance. The discussion covers real-world applications across elite athletes, aging populations, and neurocognitive conditions, while also addressing key questions around treatment frequency, safety, and effectiveness. Overall, this episode bridges the gap between emerging science and practical outcomes in modern regenerative care.Relevant links:Genesis Contact Information1-855-320-7559www.genesisregenerative.compatient-inquiry@genesisregenerative.comclinician-inquiry@genesisregenerative.com Dr. Jacobson Contact InformationMark Jacobson, M.D.Genesis Medical Director – MusculoskeletalMedical Imaging & Therapeutics, Lady Lake, FloridaFounder & Medical Directorwww.mitflorida.comDr. Bregman Contact InformationPeter Bregman, DPMGenesis Medical Director – Foot, Ankle, NeuropathyBregman Foot-Ankle & Nerve Center, Las Vegas, NVFounder & Medical Directorwww.bregmanfance.com Prof. Dr. Bankole Johnson Contact InformationProfessor Bankole Johnson,DSc, MD, MBChB, MPhil, DFAPA, FRCPysch, DAASCPGenesis Medical Director – Neuro & CognitiveMiami Stem Cell Clinic, Miami, FLFounder & Medical Directorwww.miamistemcell.clinicDisclaimer:The information provided in this podcast episode is for entertainment purposes and is NOT MEDICAL ADVICE. If you have any questions about your health, contact a medical professional. This content is strictly the opinions of Lucas Aoun and is for informational and entertainment purposes only. It is not intended to provide medical advice or to take the place of medical advice or treatment from a personal physician. All viewers of this content are advised to consult with their doctors or qualified health professionals regarding specific health questions. Neither Lucas Aoun nor the publisher of this content takes responsibility for possible health consequences of any person or persons reading or following the information in this content. All consumers of this content especially taking prescription or over-the-counter medications should consult their physician before beginning any nutritional, supplement or lifestyle program.Timestamps 0:00 Intro0:52 Meet the Experts3:53 What is RPA?6:14 Limits of Current Treatments12:41 Steroids vs Healing13:42 Athletes vs Everyday Recovery16:50 Brain and Neuro Cases24:32 Evidence and Ethics25:57 Real Patient Results30:55 Autoimmune Effects32:10 Rapid Injury Recovery33:50 Avoiding Surgery Case35:50 How RPA is Delivered36:35 Broader Applications49:52 Vision Applications51:01 Safety vs Other Treatments56:00 Outro Hosted on Acast. See acast.com/privacy for more information.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Thijs Spoor, CEO at Perspective Therapeutics,  a company developing Pb 212 (lead)-based therapeutics, talks about why radiopharmaceuticals are surging again and why biodistribution is the make-or-break variable when your payload is a radioactive isotope. Thijs discusses the reasons behind Perspective's investment in a proprietary generator for therapeutic production, manufacturing and delivery strategy, workforce constraints, and building a clinical strategy around receptor positivity across tumor types. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Imagine being able to track your brain health before serious decline sets in, understand your personal risk factors, and intervene early enough to help prevent dementia rather than simply react to it.In this episode of The TechEd Podcast, Matt Kirchner talks with Christin Glorioso, MD, PhD, founder and CEO of NeuroAge Therapeutics, about one of the most intriguing frontiers in health and longevity right now: whether brain aging can actually be measured, influenced, and in some cases pushed back. If you've paid attention to the rise of biohacking, brain games, cognitive optimization, or the broader longevity movement, this conversation gets underneath the trend and into the science.Glorioso explains how brain MRI, cognitive testing, blood biomarkers, genetics, and AI can be used together to create a more individualized view of brain health. More broadly, the conversation shows how brain health is starting to shift from late-stage treatment toward earlier measurement, prevention, and ongoing optimization.In this episode:Why one of the biggest assumptions in dementia research may have been wrong for years  The 65% number that could completely change how you think about Alzheimer's riskWhy brain aging starts earlier than almost anyone realizes, and what that means for prevention  Whether you can actually make your brain younger, not just protect it from declineThe 9 daily factors that may matter more than any miracle supplement or trend  How AI is enabling faster research and more personalized interventionA roadmap for accessible tests + personalized recommendations for a healthier brain3 Big Takeaways from this Episode:1. Dementia is not one disease, and treating it like one has held the field back. Glorioso argues that Alzheimer's has been approached too narrowly for too long, with the pharmaceutical industry spending decades focused almost entirely on amyloid. Her point is bigger than one protein: brain decline is multifactorial, which means future progress will depend on earlier diagnosis and more personalized intervention.  2. Brain aging starts earlier than most people realize, but it is not a fixed downhill slide. In the episode, Glorioso says measurable shrinkage in the hippocampus begins in the mid-20s and accelerates with age. She also points to evidence that targeted exercise can increase volume in that same brain region, making the conversation far more hopeful than most people expect.  3. You're more in control of your brain health than you may realize. Glorioso cites research suggesting that up to 65% of Alzheimer's cases may be preventable through lifestyle interventions, then grounds that claim in concrete areas like exercise, sleep, stress, diet, metabolic health, and social connection. That turns brain health from an abstract fear into something people can measure, manage, and improve over time.Resources in this Episode:NeuroAge TherapeuticsFollow Christin on SubstackVisit the episode page for the rest of the resources: https://techedpodcast.com/glorioso/We want to hear from you! Send us a text.Instagram - Facebook - YouTube - TikTok - Twitter - LinkedIn

Recorded at the 2026 SCbio Annual Conference in Charleston, Heather and Matthew welcome Ken Webb, Professor of Bioengineering at Clemson University and Co‑Founder and President of NeuroHope Therapeutics. We have an exciting conversation about how Ken's research team is developing and commercializing novel drug‑delivery technologies aimed at treating central nervous system trauma, including spinal cord and traumatic brain injuries. Ken also reflects on his journey as an academic entrepreneur, the role of SCbio and other partners in supporting early‑stage life sciences startups, and what he sees ahead for innovation at the intersection of science and patient care. Tune in for insights on cutting‑edge research with a life-changing impact.

David Stamler, CEO of Alterity Therapeutics, is developing a drug to treat multiple system atrophy (MSA), a rare and rapidly progressing neurodegenerative disease that often presents as Parkinson's disease but is distinct and more aggressive. There is no single genetic cause or specific biomarker, making accurate diagnosis a significant challenge. The lead drug is a novel small molecule designed to manage excess reactive iron in the brain, which drives the disease, and may be effective for other neurodegenerative diseases involving iron dysregulation. David explains, "Multiple system atrophy is a rare disease, and that's part of the reason people may not know so much about it. It is a neurodegenerative disease, and as the name implies, there are multiple regions of the brain that are affected, hence the term multiple systems that are governed by those regions of the brain. And as the disease progresses, some of these regions degenerate, and you get abnormal function in various areas."   "Now, we like to characterize the disease as a Parkinsonian disorder, which means early on, it can look like Parkinson's disease. And that's kind of a good descriptor to help people understand what it might look like, but it's distinct from Parkinson's disease, and it progresses a lot faster, a lot more rapidly. So it's a disease that people don't know about, probably because no one famous has been diagnosed with MSA, although I'm sure various famous people have probably had the disease and maybe didn't know it."  #AlterityTherapeutics #MultipleSystemAtrophy #MSAAwareness #NeurodegenerativeDisease #Biotech #Phase3 #Neurology #MSA #ClinicalTrials #AlterityTherapeutics #ATH434 #Biotech #RareDisease #Neurodegeneration #DrugDevelopment #MedicalBreakthrough #IronChaperone Alteritytx.com Download the transcript here  

David Stamler, CEO of Alterity Therapeutics, is developing a drug to treat multiple system atrophy (MSA), a rare and rapidly progressing neurodegenerative disease that often presents as Parkinson's disease but is distinct and more aggressive. There is no single genetic cause or specific biomarker, making accurate diagnosis a significant challenge. The lead drug is a novel small molecule designed to manage excess reactive iron in the brain, which drives the disease, and may be effective for other neurodegenerative diseases involving iron dysregulation. David explains, "Multiple system atrophy is a rare disease, and that's part of the reason people may not know so much about it. It is a neurodegenerative disease, and as the name implies, there are multiple regions of the brain that are affected, hence the term multiple systems that are governed by those regions of the brain. And as the disease progresses, some of these regions degenerate, and you get abnormal function in various areas."   "Now, we like to characterize the disease as a Parkinsonian disorder, which means early on, it can look like Parkinson's disease. And that's kind of a good descriptor to help people understand what it might look like, but it's distinct from Parkinson's disease, and it progresses a lot faster, a lot more rapidly. So it's a disease that people don't know about, probably because no one famous has been diagnosed with MSA, although I'm sure various famous people have probably had the disease and maybe didn't know it."  #AlterityTherapeutics #MultipleSystemAtrophy #MSAAwareness #NeurodegenerativeDisease #Biotech #Phase3 #Neurology #MSA #ClinicalTrials #AlterityTherapeutics #ATH434 #Biotech #RareDisease #Neurodegeneration #DrugDevelopment #MedicalBreakthrough #IronChaperone Alteritytx.com Listen to the podcast here

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech we speak with Dr. Marc Hedrick, M.D., President and CEO at Plus Therapeutics, about the company's pivot from cell therapy to radiotherapeutics for brain cancers, and what's behind the choice of Rhenium-186 as the radioisotope for its lead development candidate, Reyobiq. We'll talk about Plus Therapeutics' diagnostic subsidiary, CNSide, and hear from Marc about recent FDA meetings and the agency's attitude toward novel radiotherapeutics.      Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech we speak with Rahul Aras, Ph.D., President and CEO at Iterion Therapeutics, about capital efficient drug development in oncology and progressing a novel therapeutic with relatively small funding amounts. Iterion is a clinical stage company developing cancer therapeutics targeting the Wnt/β-catenin pathway, a known signaling target in oncology, but one that has confounded drug development efforts for decades. Rahul talks about his path from academia to company building and early work in gene therapy, Iterion's partnership strategy, and operating a biotech in the Houston, Texas clinical hub. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

If you have liver problems, gut issues, or you're missing a gallbladder, Nurse Doza has a protocol built specifically for you. In this episode, he breaks down the Good Poops Protocol — three targeted supplements from MSW Nutrition that work together to support your gut, liver, and gallbladder function. Because here's the truth: your health starts in your gut, and when things are working the way they should, you'll know it — because you'll finally have good poops. Featured Partner: MSW Nutrition — The Good Poops Protocol The Good Poops Protocol from MSW Nutrition is a three-supplement system designed by Nurse Doza to address the interconnected health of your gut, liver, and gallbladder — even if you've had yours removed. It includes Liver Boost, Berberine Plus, and the Gut powder, each targeting a specific piece of your digestive health puzzle. If you've dealt with bloating, constipation, sluggish digestion, or been told your liver or gut "looks fine" when you know it isn't, this protocol was designed for exactly that.